These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2289217)

  • 61. [The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
    Mertz DP; Loewer H; Suermann I
    Med Klin; 1979 Dec; 74(51-52):1953-6. PubMed ID: 542179
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Relation between serum lipoprotein metabolism and biliary lipid metabolism].
    Leiss O; von Bergmann K
    Klin Wochenschr; 1983 Jun; 61(12):579-92. PubMed ID: 6876687
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
    Gajdos M; Mongiellová V; Huttová D; Cibulová L; Krivosíková Z; Spustová V; Dzúrik R
    J Cardiovasc Pharmacol; 2001 Nov; 38(5):651-6. PubMed ID: 11602811
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dietary soya lecithin decreases plasma triglyceride levels and inhibits collagen- and ADP-induced platelet aggregation.
    Brook JG; Linn S; Aviram M
    Biochem Med Metab Biol; 1986 Feb; 35(1):31-9. PubMed ID: 3778675
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Effect of bezamidine on plasma cholesterol and triglyceride levels in patients with familial hyperlipoproteinemia].
    Kukharchuk VV; Koshechkin VA; Konovalov GA; Rozhkova TA; Solov'eva EIu
    Kardiologiia; 1990 Dec; 30(12):16-8. PubMed ID: 2097388
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.
    Vessby B; Lithell H; Ledermann H
    Atherosclerosis; 1982 Jul; 44(1):113-8. PubMed ID: 7115473
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Therapy of hyperlipoproteinemia type IIa and IIb with etiroxate-HCl. Dose-response comparison].
    Banz H; Gall FP
    Fortschr Med; 1979 Nov; 97(42):1942-1947. PubMed ID: 520990
    [TBL] [Abstract][Full Text] [Related]  

  • 68. CI-924 effects on plasma lipids in patients with type II and type IV hyperlipoproteinaemia.
    Corder CN; Kloer HU; Price MD
    Eur J Clin Pharmacol; 1989; 37(5):477-81. PubMed ID: 2598985
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial.
    Illingworth DR; Olsen GD; Cook SF; Sexton GJ; Wendel HA; Connor WE
    Atherosclerosis; 1982 Aug; 44(2):211-21. PubMed ID: 6753860
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Results of a phase IV study carried out with acipimox in type II diabetic patients with concomitant hyperlipoproteinaemia.
    Lavezzari M; Milanesi G; Oggioni E; Pamparana F
    J Int Med Res; 1989; 17(4):373-80. PubMed ID: 2676653
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Effect of phenofibrate on serum cholesterol and triglyceride concentration in patients with primary hyperlipoproteinemia].
    Cieślicka T; Paradowski S
    Pol Arch Med Wewn; 1983; 70(5-6):223-9. PubMed ID: 6677885
    [No Abstract]   [Full Text] [Related]  

  • 72. Effect of deoxycholic acid on lipoprotein and apolipoprotein levels in patients with familial hypercholesterolemia.
    Leuven JA; Havekes L; Kempen HJ
    Atherosclerosis; 1986 Oct; 62(1):21-5. PubMed ID: 3535814
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Clinical study of fenofibrate in hyperlipoproteinemias].
    Ducobu J
    Acta Clin Belg; 1980; 35(3):148-54. PubMed ID: 7456965
    [No Abstract]   [Full Text] [Related]  

  • 74. Effect of oral mesoglycan on plasma lipoprotein concentration and on lipoprotein lipase activity in primary hyperlipoproteinemia.
    Postiglione A; De Simone B; Rubba P; Lamenza F; Montefusco S; Mastranzo P
    Pharmacol Res Commun; 1984 Jan; 16(1):1-8. PubMed ID: 6230680
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Characterization of subpopulations of apo B containing lipoproteins separated by analytical capillary isotachophoresis.
    Nowicka G; Schmitz G
    Klin Wochenschr; 1990; 68 Suppl 22():119-20. PubMed ID: 2087068
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Plasma carnitine and lipid-lowering drugs.
    Nestruck AC; Pande SV; Davignon J
    Atherosclerosis; 1985 Jun; 55(3):353-6. PubMed ID: 4015753
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Increased excretion of fecal fat in hyperlipidemic patients.
    Nagasaki A; Maruhama Y
    Tohoku J Exp Med; 1980 May; 131(1):99-100. PubMed ID: 7404579
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis.
    Sirtori CR; Gianfranceschi G; Sirtori M; Bernini F; Descovich G; Montaguti U; Fuccella LM; Musatti L
    Atherosclerosis; 1981; 38(3-4):267-71. PubMed ID: 7225165
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Changes in serum lipoprotein pattern following bezafibrate. Differential effects in type IIa and in type IIb hyperlipoproteinemic patients.
    Sommariva D; Tirrito M; Bonfiglioli D; Pogliaghi I; Branchi A; Ottomano C; Bellintani L
    Pharmacol Res Commun; 1985 Dec; 17(12):1181-91. PubMed ID: 4095126
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein B levels in patients with type II and IV hyperlipoproteinemia].
    Sznajderman M
    Pol Arch Med Wewn; 1983; 70(5-6):259-69. PubMed ID: 6677890
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.